02.12.2012 Views

2011 Anniversary Yearbook - EUFEPS today and history

2011 Anniversary Yearbook - EUFEPS today and history

2011 Anniversary Yearbook - EUFEPS today and history

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

Network<br />

Environment <strong>and</strong> Pharmaceuticals<br />

European Federation for Pharmaceutical Sciences<br />

Scope <strong>and</strong> Aim<br />

Pharmaceuticals are indispensable for a high quality of life. Their use however also has an<br />

environmental downside that needs to be h<strong>and</strong>led. In recent years, a huge amount of data<br />

has been collected, demonstrating the widespread of a variety of active drug ingredients in<br />

the aquatic environment <strong>and</strong> sporadically even in drinking water. Being only insufficiently<br />

eliminated in the conventional sewage treatment plants, there is growing evidence that the<br />

substances <strong>and</strong> their metabolites have adverse effects on aquatic <strong>and</strong> in some cases terrestrial<br />

organisms on both the individual <strong>and</strong> population level. How to adequately address<br />

these issues? The Network has been initiated to address scientific achievements <strong>and</strong> discuss<br />

various issues on exposure of pharmaceuticals to the environment, including attempts<br />

towards global harmonisation.<br />

Contact Point<br />

Lennart Dencker lennart.dencker@farmbio.uu.se<br />

Network<br />

Food-Drug Synergies<br />

European Federation for Pharmaceutical Sciences<br />

Scope <strong>and</strong> aim<br />

This Network initiative is new. The idea is to assemble the industry-academia-regulatory<br />

triangle to work on topics which cross between food science <strong>and</strong> pharmaceutical sciences.<br />

Topics would be, for example: Personalised nutrition <strong>and</strong> personalised medicine; special<br />

needs (the sick, children, the elderly); sharing technology to evaluate product performance;<br />

best practice to be communicated to public bodies; encouraging liaison across Europe to<br />

create enterprise; <strong>and</strong> to explore new neutraceutical concepts.<br />

Contact point<br />

David Featherston DFE@biopeople.ku.dk<br />

36

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!